INmune Bio Inc. has highlighted a recently published peer-reviewed article discussing the therapeutic potential of mesenchymal stromal cell $(MSC)$ therapies, including its own CORDStrom™ platform. The overview, published in the journal Cytotherapy, was co-authored by Dr. Nikita M. Patel, INmune Bio's lead scientist for CORDStrom™ R&D. The article reviews current knowledge and critical gaps in MSC research, focusing on topics such as systemic and local delivery and in vivo persistence. While the results were published in the journal and not presented at a conference, INmune Bio noted that CORDStrom™ is initially being developed for Recessive Dystrophic Epidermolysis Bullosa (RDEB), with regulatory filings expected in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597425-en) on December 05, 2025, and is solely responsible for the information contained therein.